Cargando…
Targeting the androgen receptor to enhance NK cell killing efficacy in bladder cancer by modulating ADAR2/circ_0001005/PD-L1 signaling
Although androgen receptor (AR) can influence bladder cancer (BCa) initiation and progression, its impact on tumor immune escape remains unclear. Here, we found that targeting AR could enhance natural killer (NK) cell tumor-killing efficacy by decreasing PD-L1 expression. Both antiandrogen treatment...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group US
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9750871/ https://www.ncbi.nlm.nih.gov/pubmed/35915245 http://dx.doi.org/10.1038/s41417-022-00506-w |
_version_ | 1784850351916056576 |
---|---|
author | Liu, Qing You, Bosen Meng, Jialin Huang, Chi-Ping Dong, Guanglu Wang, Ronghao Chou, Fuju Gao, Shan Chang, Chawnshang Yeh, Shuyuan Xu, Wanhai |
author_facet | Liu, Qing You, Bosen Meng, Jialin Huang, Chi-Ping Dong, Guanglu Wang, Ronghao Chou, Fuju Gao, Shan Chang, Chawnshang Yeh, Shuyuan Xu, Wanhai |
author_sort | Liu, Qing |
collection | PubMed |
description | Although androgen receptor (AR) can influence bladder cancer (BCa) initiation and progression, its impact on tumor immune escape remains unclear. Here, we found that targeting AR could enhance natural killer (NK) cell tumor-killing efficacy by decreasing PD-L1 expression. Both antiandrogen treatment and AR knockdown effectively reduced membrane PD-LI expression to facilitate NK cell-mediated BCa cell killing by downregulating circ_0001005. Mechanistically, AR upregulated circRNA circ_0001005 expression via the RNA-editing gene ADAR2. circ_0001005 competitively sponged the miRNA miR-200a-3p to promote PD-L1 expression. A preclinical BCa xenograft mouse model further confirmed this newly identified signaling using the small molecule circ_0001005-shRNA to improve NK cell killing of BCa tumor cells. Collectively, these results suggest that targeting the newly identified ADAR2/circ_0001005/miR-200a-3p/PD-L1 pathway to impact antitumor immunity may suppress progression and boost immunotherapeutic efficacy in BCa. |
format | Online Article Text |
id | pubmed-9750871 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Nature Publishing Group US |
record_format | MEDLINE/PubMed |
spelling | pubmed-97508712022-12-16 Targeting the androgen receptor to enhance NK cell killing efficacy in bladder cancer by modulating ADAR2/circ_0001005/PD-L1 signaling Liu, Qing You, Bosen Meng, Jialin Huang, Chi-Ping Dong, Guanglu Wang, Ronghao Chou, Fuju Gao, Shan Chang, Chawnshang Yeh, Shuyuan Xu, Wanhai Cancer Gene Ther Article Although androgen receptor (AR) can influence bladder cancer (BCa) initiation and progression, its impact on tumor immune escape remains unclear. Here, we found that targeting AR could enhance natural killer (NK) cell tumor-killing efficacy by decreasing PD-L1 expression. Both antiandrogen treatment and AR knockdown effectively reduced membrane PD-LI expression to facilitate NK cell-mediated BCa cell killing by downregulating circ_0001005. Mechanistically, AR upregulated circRNA circ_0001005 expression via the RNA-editing gene ADAR2. circ_0001005 competitively sponged the miRNA miR-200a-3p to promote PD-L1 expression. A preclinical BCa xenograft mouse model further confirmed this newly identified signaling using the small molecule circ_0001005-shRNA to improve NK cell killing of BCa tumor cells. Collectively, these results suggest that targeting the newly identified ADAR2/circ_0001005/miR-200a-3p/PD-L1 pathway to impact antitumor immunity may suppress progression and boost immunotherapeutic efficacy in BCa. Nature Publishing Group US 2022-08-01 2022 /pmc/articles/PMC9750871/ /pubmed/35915245 http://dx.doi.org/10.1038/s41417-022-00506-w Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Liu, Qing You, Bosen Meng, Jialin Huang, Chi-Ping Dong, Guanglu Wang, Ronghao Chou, Fuju Gao, Shan Chang, Chawnshang Yeh, Shuyuan Xu, Wanhai Targeting the androgen receptor to enhance NK cell killing efficacy in bladder cancer by modulating ADAR2/circ_0001005/PD-L1 signaling |
title | Targeting the androgen receptor to enhance NK cell killing efficacy in bladder cancer by modulating ADAR2/circ_0001005/PD-L1 signaling |
title_full | Targeting the androgen receptor to enhance NK cell killing efficacy in bladder cancer by modulating ADAR2/circ_0001005/PD-L1 signaling |
title_fullStr | Targeting the androgen receptor to enhance NK cell killing efficacy in bladder cancer by modulating ADAR2/circ_0001005/PD-L1 signaling |
title_full_unstemmed | Targeting the androgen receptor to enhance NK cell killing efficacy in bladder cancer by modulating ADAR2/circ_0001005/PD-L1 signaling |
title_short | Targeting the androgen receptor to enhance NK cell killing efficacy in bladder cancer by modulating ADAR2/circ_0001005/PD-L1 signaling |
title_sort | targeting the androgen receptor to enhance nk cell killing efficacy in bladder cancer by modulating adar2/circ_0001005/pd-l1 signaling |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9750871/ https://www.ncbi.nlm.nih.gov/pubmed/35915245 http://dx.doi.org/10.1038/s41417-022-00506-w |
work_keys_str_mv | AT liuqing targetingtheandrogenreceptortoenhancenkcellkillingefficacyinbladdercancerbymodulatingadar2circ0001005pdl1signaling AT youbosen targetingtheandrogenreceptortoenhancenkcellkillingefficacyinbladdercancerbymodulatingadar2circ0001005pdl1signaling AT mengjialin targetingtheandrogenreceptortoenhancenkcellkillingefficacyinbladdercancerbymodulatingadar2circ0001005pdl1signaling AT huangchiping targetingtheandrogenreceptortoenhancenkcellkillingefficacyinbladdercancerbymodulatingadar2circ0001005pdl1signaling AT dongguanglu targetingtheandrogenreceptortoenhancenkcellkillingefficacyinbladdercancerbymodulatingadar2circ0001005pdl1signaling AT wangronghao targetingtheandrogenreceptortoenhancenkcellkillingefficacyinbladdercancerbymodulatingadar2circ0001005pdl1signaling AT choufuju targetingtheandrogenreceptortoenhancenkcellkillingefficacyinbladdercancerbymodulatingadar2circ0001005pdl1signaling AT gaoshan targetingtheandrogenreceptortoenhancenkcellkillingefficacyinbladdercancerbymodulatingadar2circ0001005pdl1signaling AT changchawnshang targetingtheandrogenreceptortoenhancenkcellkillingefficacyinbladdercancerbymodulatingadar2circ0001005pdl1signaling AT yehshuyuan targetingtheandrogenreceptortoenhancenkcellkillingefficacyinbladdercancerbymodulatingadar2circ0001005pdl1signaling AT xuwanhai targetingtheandrogenreceptortoenhancenkcellkillingefficacyinbladdercancerbymodulatingadar2circ0001005pdl1signaling |